Lab Notebook 2024

Callum Malcolm

Contents

uary 2024	
oruary 2024	
·	
rch 2024	
nday 24-03-2024	
MR - CD20 Flow EpiDrug Pretreatment	
Protocol	
Results	
esday 25-03-2024	
RTX EC50_250324 RBL2 - Seeding	
Plate seeding protocol:	
RBL2 RTX DP - Dose 1	
Dosing Protocol	
Plate Layout	
RBL2 RTX DP - Sample Collection Baseline	
Collection Protocol	
ursday 27-03-2024	
EC50_250325 Collection - RBL2 RTX CDC Baseline	
Results:	

LN Repository

Rack 1

• Location: Tank 2, Rack 1, Row H (Bottom)

Location	Cap ID	Description	Date
1	Grey	Empty - Marker	-
2	Ramos BC 1	Ramos RTX CDC Baseline	12/06/2024
3	Ramos BC 1	Ramos RTX CDC Baseline	12/06/2024
4	Ramos BC 1	Ramos RTX CDC Baseline	12/06/2024
5	C4 DP2	Ramos RTX CDC C4-DP2	-
6	C5 DP2	Ramos RTX CDC C5-DP2	-
7	C1 DP2	Ramos RTX CDC C1-DP2	-
8	R3 DP2	Ramos RTX CDC R3-DP2	-
9	C6 DP2	Ramos RTX CDC C6-DP2	-
10	C3 DP2	Ramos RTX CDC C3-DP2	-
11	C2 DP2	Ramos RTX CDC C2-DP2	-
12	-	-	-
13	-	-	_
14	_	-	_
15	_	-	_
16	-	-	_
17	-	-	_
18	-	-	_
19	-	-	-
20	-	-	_
21	-	-	-
22	-	-	-
23	-	-	-
24	_	_	_
25	_	_	_
26	_	_	_
27	_	_	_
28	_	_	_
29	_	_	_
30	_	-	_
31	Ramos BC 1	Ramos Barcode Pool 1	12/06/2024
32	Ramos BC 1	Ramos Barcode Pool 1	04/01/2023
33	Ramos BC 1	Ramos Barcode Pool 1 *	16/07/2024
34	Ramos BC 3	Ramos Barcode Pool 3	12/06/2024
35	Ramos BC 3	Ramos Barcode Pool 3	04/06/2024
36	Ramos BC 3	Ramos Barcode Pool 3	12/06/2024
37	Ramos BC 5	Ramos BC Pool 5	12/06/2024
38	Ramos BC 5	Ramos Barcode Pool 5	04/16/2024
39	Ramos BC 6	Ramos Barcode Pool 6	04/16/2024
40	-	-	-
41	_	_	_
42	_	_	_
43	_	_	_
44	_	_	_
45	_	_	_
46	_	_	_
47	_	_	_
41	_	=	-

Location	Cap ID	Description	Date
48		2 ocomparon	
48 49	-	_	_
49 50	_	_	_
50 51	- RBL1	- RBL1 PDX	31/07/2023
52	RBL1	RBL1 PDX	31/07/2023 $31/07/2024$
52 53	RBL1 PDX	RBL1 PDX	31/07/2024 $31/07/2024$
53 54	BLLW	BLLW PDX Pool	31/07/2024 $31/07/2024$
55 55	BLLW	BLLW PDX Pool	31/07/2024 $31/07/2024$
56	N4	N4 PDX pool	07/11/2023
57	N4	N4 PDX pool	07/11/2023
58	N2 BC	N2 Barcoded pool	11/05/2023
59	N2 BC 5	N2 barcode pool 5	29/04/2024
60	A20	A20 Cell Pool	13/10/2024
61	A20	A20 Stock	13/10/2024
62	-	-	-
63	_	-	_
64	_	-	_
65	_	-	-
66	_	-	-
67	_	_	_
68	-	-	-
69	-	-	_
70	-	-	_
71	_	-	_
72	_	-	_
73	-	-	-
74	-	-	-
75	-	-	-
76	-	-	-
77	-	-	-
78	-	-	-
79	-	-	-
80	-	-	-
81	-	-	-
82	-	-	-
83	-	-	-
84	-	-	-
85	-	-	-
86	-	-	-
87	-	-	-
88	-	-	-
89	-	-	-
90	-	-	-
91	NA	NA	NA
92	NA	NA	NA
93	NA	NA	NA
94	A20 ME	B-IP-724-1L	-
95	A20 ME	B-IP-723 NM	-
96	A20 ME	B-IP-723-2L	-
97	A20 ME	723-2R	-
98	A20 ME	723-1L	-
99	A20 ME	710 NM - A20 Mouse Experiment	-

Location	Cap ID	Description	Date
100	NA	NA	NA

January 2024

February 2024

March 2024

Monday 24-03-2024

MR - CD20 Flow EpiDrug Pretreatment

Protocol

- 1. 1x10e6 cells from each treatment group were split into 3 wells of a 96-well plate
- 2. Plate spun at 300xg 5 min and supernatant discarded
- 3. Cells were resuspeded in FACS Staining buffer
- 1ul CD20 (BD Cat# 562873) per 250uL
- 12 uL in 3000uL
- 4. Plate inbuated in the dark for 20min at 4C
- 5. Plate spun at 300 xg 5 min and supernatant discarded
- 6. Samples were resuspended in 400uL PBS and transferred to FACS tubes

Results

• No clear alteration of CD20 expression due to Epigenetic drug pretreatment

Tuesday 25-03-2024

RTX $EC50_250324$ RBL2 - Seeding

- \bullet Seeded an EC50 experiment comparing the effects of RTX on Baseline RBL2 in the presence of 25% NHS
- Seeded 1 plates with the same RBL2 Baseline population
- Used Rixathon (Catalogue#:)

Plate seeding protocol:

1. Diluted cell suspension to seed 10000 cells/well in $50\mu L$ amounts

						Stock	Media
	Cell		Required	Required		Volume	Volume
Plate	Line	Cell Count	Cell total	Volume total	CS cells/mL	(uL)	(mL)
Plate	RBL2	5.65×10^{5}	7.00×10^{5}	3.5	1.61×10^{5}	1238.9	2.2611
1							


- 2. Made RTX dilutions and added to respective wells in $25\mu L$
 - [RTX stock] = 10.3 mg/mL
 - Drug volumes are added in triplicate
 - Drug volumes are being added consititute 1/4 of well volume:

- [RTX working] needs to be 4x [RTX well]
 - 6 wells per condition, $25\mu L$ per well ~ minimum of $150\mu L$ per condition needed (recommend $200\mu L$)

Dilution ID	Well [RTX] (µg/mL)	RTX Source	Source Volume (μL)	Media Volume (μL)	Working Stock [RTX] $(\mu g/mL)$
RTX 1	20.0	Stock	4.650000000000000004	595.4	79.8
RTX 2	10.0	RTX 1	300	300.0	39.9
RTX 3	5.0	RTX 2	300	300.0	20.0
RTX 4	2.5	RTX 3	300	300.0	10.0
RTX 5	1.2	RTX 4	300	300.0	5.0
RTX 6	0.6	RTX 5	300	300.0	2.5
RTX 7	0.3	RTX 6	300	300.0	1.2
RTX 8	0.2	RTX 7	300	300.0	0.6
RTX 9	0.1	RTX 8	300	600.0	0.3
CNTR	0.0	-	-	1000.0	0.0

- 3. Added HIAS/NHS to indicated wells
- $25\mu L/well$
- Final well volume = 25% Serum (HIAS/NHS)
- 4. Plate is incubated for 48 hrs at 37C

EC50_250324 CDC Test RBL2



RBL2 RTX DP - Dose 1

- Began RTX CDC In Vitro dosing
- Seeded RBL2 into 2x 6 well plates


Dosing Protocol

- 1. Count CS and dilute to $2x10^5$ cells in 1 mL
- If cell count is below either re-culture or add required CS amount, spin down, and resuspend in 1mL
- 2. Add 1mL of cell suspension containing $2x10^5$ cells to respective wells of 6-well plate


- 3. Made RTX dilutions and added to respective Rx wells in 500μ L
 - [RTX stock] = 10.3 mg/mL
 - Drug volumes are being added consititute 1/4 of well volume:
 - [RTX working] needs to be 4x [RTX well]
 - 6 wells per RTX dosing, 500μ L per well ~ minimum of 3000μ L per condition needed (recommend 3500μ L)
 - $\bullet~1.4~\mathrm{uL}$ RTX stock in $3.5\mathrm{mL}$ media
 - 500μ L media added to Cx wells
- 4. Added NHS to all wells
- $500\mu L/well$
- Final well volume = 25% Serum (NHS)
- 4. Plates incubated for 24 hrs at 37C

Plate Layout

RBL2 RTX DP1 Control 250325



RBL2 RTX DP1 RR-RBL2 250325



RBL2 RTX DP - Sample Collection Baseline

Collection Protocol

- 1. 1×10^6 cells added to eppendorf tubes
- 2. Spun down @ max speed @ 4C
- 3. Supernatant removed
- 4. Pellets flash frozen
- 5. Pellets saved at -80C

Thursday 27-03-2024

EC50_250325 Collection - RBL2 RTX CDC Baseline

- Collected plates seeded on 25-03-2025
- EC Plate collection protocol:
 - 1. Added $20\mu L$ Cell Titre Blue (CTB) to each conditioned well
 - $-20\mu L \text{ CTB}/100\mu L$ of conditioned well recommended by manufacturer
 - 2. Incubated for 2hr at 37C
 - 3. Read on plate reader according to Cell Titre Blue Protocol

Results:

- HIAS impact on RTX CDC similar to previous experiments
- NHS impact on RTX CDC is consistent with previous experiments

RBL2 Baseline RTX +/- Serum

